Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CFO Julie B. Feder sold 25,131 shares of Aura Biosciences stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total transaction of $302,325.93. Following the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Aura Biosciences Trading Down 0.8 %

AURA traded down $0.09 during trading hours on Monday, hitting $11.65. The company’s stock had a trading volume of 486,588 shares, compared to its average volume of 176,424. The business’s 50-day moving average price is $8.66 and its 200-day moving average price is $8.07. Aura Biosciences, Inc. has a 12 month low of $5.99 and a 12 month high of $12.38. The stock has a market cap of $577.18 million, a price-to-earnings ratio of -6.26 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.04. On average, analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Institutional Investors Weigh In On Aura Biosciences

Several large investors have recently bought and sold shares of AURA. Regency Capital Management Inc. DE increased its position in Aura Biosciences by 11.4% in the first quarter. Regency Capital Management Inc. DE now owns 785,136 shares of the company’s stock worth $6,163,000 after purchasing an additional 80,162 shares during the last quarter. American International Group Inc. increased its position in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares during the last quarter. Levin Capital Strategies L.P. increased its position in Aura Biosciences by 11.2% during the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after acquiring an additional 11,200 shares during the last quarter. Virtu Financial LLC bought a new position in Aura Biosciences during the first quarter valued at $144,000. Finally, Bank of New York Mellon Corp increased its position in Aura Biosciences by 51.4% during the second quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock valued at $1,081,000 after acquiring an additional 48,549 shares during the last quarter. Institutional investors own 96.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on AURA. HC Wainwright lifted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday. BTIG Research boosted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Finally, Scotiabank boosted their target price on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.